Image provider Jaap Arrians/NurPhoto (via Getty Images)
The makers of Ozempic and Wegovy have received government approval to sell their products to reduce the risk of heart attack, heart disease and stroke. This could help expand insurance coverage for highly popular drugs.
in press releasethe Food and Drug Administration announced that Novo Nordisk, the Danish company that developed the hugely popular weight loss injectable, received its first heart health approval specifically for people who are overweight or obese. Did.
“Wegovy is also approved for use in the prevention of life-threatening cardiovascular events in obese or overweight adults with cardiovascular disease,” John Sharetz, the FDA’s diabetes and obesity leader, said in a press release. “This is the first weight-loss drug in the world.” “This patient population is at high risk for cardiovascular death, heart attack, and stroke. Providing treatment options proven to reduce this cardiovascular risk is a major advance for public health.”
last august, Novo announced Semaglutide, the active ingredient in both Wigovy and Ozempic, has shown significant benefits for heart health in large-scale human trials. Specifically, the 2.4 milligram dose used in Wegovy showed an association with lower heart disease risk compared to the 1 mg version used in Ozempic.
Beneficial uses of this drug belong to a class of medicines known as. GLP-1 agonist Mimicking the feeling of fullness in the stomach is just the latest in a growing list. Positive side effects of semaglutide — Unfortunately, this list is tailored with rap sheets ranging from mild to severe. problem is linked to.
The popularity of semaglutide is FDA approved Wegovy, a high-dose injectable weight-loss treatment, is disappearing from store shelves despite insurance companies’ reluctance to shell out the big bucks, leaving some people wondering if they’ll go without it. , resulting in the search for unregulated and often dangerous gray market alternatives.
in Interview NPRMartha Gulati, a cardiologist at Cedars-Sinai Medical Center in Los Angeles, estimates that up to 70 percent of her patients may be eligible for this medication. not yet covered by many people Insurance company.
“My hope is that insurance companies will start to understand that this is not a vanity drug,” Gulati said.
More details on the benefits of semaglutide: Semaglutide can slow the progression of diabetic kidney disease
